LOCUS       MAVS_HUMAN               540 aa            linear   PRI 02-DEC-2020
DEFINITION  RecName: Full=Mitochondrial antiviral-signaling protein;
            Short=MAVS; AltName: Full=CARD adapter inducing interferon beta;
            Short=Cardif; AltName: Full=Interferon beta promoter stimulator
            protein 1; Short=IPS-1; AltName: Full=Putative
            NF-kappa-B-activating protein 031N; AltName:
            Full=Virus-induced-signaling adapter; Short=VISA.
ACCESSION   Q7Z434
VERSION     Q7Z434.2
DBSOURCE    UniProtKB: locus MAVS_HUMAN, accession Q7Z434;
            class: standard.
            extra
            accessions:A8K6X0,B2BD33,B2BD34,F5H6C8,M1P2Z0,Q2HWT5,Q3I0Y2,Q5T7I6,
            Q86VY7,Q9H1H3,Q9H4Y1,Q9H8D3,Q9ULE9
            created: May 10, 2004.
            sequence updated: May 10, 2004.
            annotation updated: Dec 2, 2020.
            xrefs: DQ174270.1, AAZ80417.1, DQ167126.1, ABA54890.1, DQ181928.1,
            ABA19229.1, AB232371.1, BAE79738.1, EF467323.1, ABR24161.1,
            EF467324.1, ABR24162.1, KC415005.1, AGF94754.1, AB033097.1,
            BAA86585.1, AB097003.1, BAC77356.1, AK023799.1, BAB14684.1,
            AK123956.1, BAC85734.1, AK130992.1, BAC85473.1, AK291785.1,
            BAF84474.1, AK296897.1, BAG59455.1, AL109804.41, AL353194.13,
            CH471133.3, EAX10481.1, BC044952.1, AAH44952.1, NP_001193420.1,
            NP_065797.2, 2MS7_A, 2MS7_B, 2MS7_C, 2MS7_D, 2MS7_E, 2MS7_F,
            2MS7_G, 2MS7_H, 2MS7_I, 2MS7_J, 2MS7_K, 2MS7_L, 2MS7_M, 2MS7_N,
            2MS7_O, 2MS7_P, 2MS7_Q, 2MS7_R, 2MS7_S, 2MS7_T, 2MS7_U, 2MS8_A,
            2VGQ_A, 3J6C_A, 3J6J_A, 3J6J_B, 3J6J_C, 3J6J_D, 3J6J_E, 3J6J_G,
            3J6J_I, 3J6J_L, 3RC5_B, 4P4H_I, 4P4H_J, 4P4H_K, 4P4H_L, 4P4H_M,
            4P4H_N, 4P4H_O, 4P4H_P, 4Z8M_C, 4Z8M_D, 5JEK_C, 5JEK_D
            xrefs (non-sequence databases): CCDS:CCDS33437.1, CCDS:CCDS56176.1,
            PDBsum:2MS7, PDBsum:2MS8, PDBsum:2VGQ, PDBsum:3J6C, PDBsum:3J6J,
            PDBsum:3RC5, PDBsum:4P4H, PDBsum:4Z8M, PDBsum:5JEK, BMRB:Q7Z434,
            SMR:Q7Z434, BioGRID:121570, DIP:DIP-35445N, IntAct:Q7Z434,
            MINT:Q7Z434, STRING:9606.ENSP00000401980, GlyGen:Q7Z434,
            iPTMnet:Q7Z434, MetOSite:Q7Z434, PhosphoSitePlus:Q7Z434,
            SwissPalm:Q7Z434, BioMuta:MAVS, DMDM:47115748, CPTAC:CPTAC-977,
            EPD:Q7Z434, jPOST:Q7Z434, MassIVE:Q7Z434, MaxQB:Q7Z434,
            PaxDb:Q7Z434, PeptideAtlas:Q7Z434, PRIDE:Q7Z434,
            ProteomicsDB:27148, ProteomicsDB:3402, ProteomicsDB:69137,
            ProteomicsDB:69138, ProteomicsDB:69139, Antibodypedia:3363,
            DNASU:57506, Ensembl:ENST00000416600, Ensembl:ENSP00000413749,
            Ensembl:ENSG00000088888, Ensembl:ENST00000428216,
            Ensembl:ENSP00000401980, GeneID:57506, KEGG:hsa:57506,
            UCSC:uc002wjw.5, CTD:57506, DisGeNET:57506,
            EuPathDB:HostDB:ENSG00000088888.17, GeneCards:MAVS, HGNC:29233,
            HPA:ENSG00000088888, MIM:609676, neXtProt:NX_Q7Z434,
            OpenTargets:ENSG00000088888, PharmGKB:PA164722208,
            eggNOG:ENOG502SAUA, GeneTree:ENSGT00510000049120,
            HOGENOM:CLU_042052_0_0_1, InParanoid:Q7Z434, OMA:HNGYREE,
            OrthoDB:887440at2759, PhylomeDB:Q7Z434, TreeFam:TF333444,
            PathwayCommons:Q7Z434, Reactome:R-HSA-168928,
            Reactome:R-HSA-5689896, Reactome:R-HSA-918233,
            Reactome:R-HSA-933541, Reactome:R-HSA-933542,
            Reactome:R-HSA-933543, Reactome:R-HSA-936440, SignaLink:Q7Z434,
            SIGNOR:Q7Z434, BioGRID-ORCS:57506, ChiTaRS:MAVS,
            EvolutionaryTrace:Q7Z434, GeneWiki:VISA_(gene), GenomeRNAi:57506,
            Pharos:Q7Z434, PRO:PR:Q7Z434, Proteomes:UP000005640, RNAct:Q7Z434,
            Bgee:ENSG00000088888, Genevisible:Q7Z434, GO:0016021, GO:0031966,
            GO:0005741, GO:0005739, GO:0005778, GO:0050700, GO:0019901,
            GO:0035591, GO:0002218, GO:0071360, GO:0042742, GO:0051607,
            GO:0045087, GO:0032480, GO:0045071, GO:0071651, GO:0002230,
            GO:0051091, GO:0043123, GO:0032727, GO:0032728, GO:0032755,
            GO:0032757, GO:0071660, GO:0002735, GO:0042307, GO:0001934,
            GO:0060760, GO:0045944, GO:0032760, GO:1904469, GO:0060340,
            GO:1900063, GO:0007165, GO:0016032, CDD:cd08811,
            InterPro:IPR031964, InterPro:IPR042144, InterPro:IPR026148,
            PANTHER:PTHR21446:SF6, Pfam:PF16739
KEYWORDS    3D-structure; Alternative splicing; Antiviral defense; Host-virus
            interaction; Immunity; Innate immunity; Membrane; Methylation;
            Mitochondrion; Mitochondrion outer membrane; Peroxisome;
            Phosphoprotein; Polymorphism; Reference proteome; Transmembrane;
            Transmembrane helix; Ubl conjugation.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
            Catarrhini; Hominidae; Homo.
REFERENCE   1  (residues 1 to 540)
  AUTHORS   Seth,R.B., Sun,L., Ea,C.K. and Chen,Z.J.
  TITLE     Identification and characterization of MAVS, a mitochondrial
            antiviral signaling protein that activates NF-kappaB and IRF 3
  JOURNAL   Cell 122 (5), 669-682 (2005)
   PUBMED   16125763
  REMARK    NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE
            SPECIFICITY, MUTAGENESIS OF THR-54 AND 67-GLY--VAL-69, INTERACTION
            WITH DDX58/RIG-I AND TRAF6, SUBCELLULAR LOCATION, AND VARIANTS
            LYS-198 AND PHE-409.
REFERENCE   2  (residues 1 to 540)
  AUTHORS   Xu,L.G., Wang,Y.Y., Han,K.J., Li,L.Y., Zhai,Z. and Shu,H.B.
  TITLE     VISA is an adapter protein required for virus-triggered IFN-beta
            signaling
  JOURNAL   Mol Cell 19 (6), 727-740 (2005)
   PUBMED   16153868
  REMARK    NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, INTERACTION WITH
            DDX58/RIG-I; IRF3; TRAF2 AND TRAF6, MUTAGENESIS OF GLN-145; GLU-155
            AND GLU-457, FUNCTION, AND VARIANT GLU-93.
REFERENCE   3  (residues 1 to 540)
  AUTHORS   Meylan,E., Curran,J., Hofmann,K., Moradpour,D., Binder,M.,
            Bartenschlager,R. and Tschopp,J.
  TITLE     Cardif is an adaptor protein in the RIG-I antiviral pathway and is
            targeted by hepatitis C virus
  JOURNAL   Nature 437 (7062), 1167-1172 (2005)
   PUBMED   16177806
  REMARK    NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH
            DDX58/RIG-I; IKBKE; CHUK AND IKBKB, FUNCTION, MUTAGENESIS OF
            CYS-508, VARIANTS LYS-198 AND PHE-409, INTERACTION WITH HCV NS3/4A
            PROTEASE (MICROBIAL INFECTION), AND PROTEOLYTIC CLEAVAGE (MICROBIAL
            INFECTION).
REFERENCE   4  (residues 1 to 540)
  AUTHORS   Kawai,T., Takahashi,K., Sato,S., Coban,C., Kumar,H., Kato,H.,
            Ishii,K.J., Takeuchi,O. and Akira,S.
  TITLE     IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I
            interferon induction
  JOURNAL   Nat Immunol 6 (10), 981-988 (2005)
   PUBMED   16127453
  REMARK    NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
            INTERACTION WITH DDX58/RIG-I; IFIH1/MDA5; FADD AND RIPK1, FUNCTION,
            AND VARIANT GLU-93.
REFERENCE   5  (residues 1 to 540)
  AUTHORS   Lad,S.P., Yang,G., Scott,D.A., Chao,T.H., Correia Jda,S., de la
            Torre,J.C. and Li,E.
  TITLE     Identification of MAVS splicing variants that interfere with
            RIGI/MAVS pathway signaling
  JOURNAL   Mol Immunol 45 (8), 2277-2287 (2008)
   PUBMED   18207245
  REMARK    NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6).
REFERENCE   6  (residues 1 to 540)
  AUTHORS   Patel,M.R., Loo,Y.M., Horner,S.M., Gale,M. Jr. and Malik,H.S.
  TITLE     Convergent evolution of escape from hepaciviral antagonism in
            primates
  JOURNAL   PLoS Biol 10 (3), e1001282 (2012)
   PUBMED   22427742
  REMARK    NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
REFERENCE   7  (residues 1 to 540)
  AUTHORS   Nagase,T., Ishikawa,K., Kikuno,R., Hirosawa,M., Nomura,N. and
            Ohara,O.
  TITLE     Prediction of the coding sequences of unidentified human genes. XV.
            The complete sequences of 100 new cDNA clones from brain which code
            for large proteins in vitro
  JOURNAL   DNA Res 6 (5), 337-345 (1999)
   PUBMED   10574462
  REMARK    NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).;
            TISSUE=Brain
REFERENCE   8  (residues 1 to 540)
  AUTHORS   Matsuda,A., Suzuki,Y., Honda,G., Muramatsu,S., Matsuzaki,O.,
            Nagano,Y., Doi,T., Shimotohno,K., Harada,T., Nishida,E., Hayashi,H.
            and Sugano,S.
  TITLE     Large-scale identification and characterization of human genes that
            activate NF-kappaB and MAPK signaling pathways
  JOURNAL   Oncogene 22 (21), 3307-3318 (2003)
   PUBMED   12761501
  REMARK    NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).;
            TISSUE=Lung fibroblast
REFERENCE   9  (residues 1 to 540)
  AUTHORS   Ota,T., Suzuki,Y., Nishikawa,T., Otsuki,T., Sugiyama,T., Irie,R.,
            Wakamatsu,A., Hayashi,K., Sato,H., Nagai,K., Kimura,K., Makita,H.,
            Sekine,M., Obayashi,M., Nishi,T., Shibahara,T., Tanaka,T.,
            Ishii,S., Yamamoto,J., Saito,K., Kawai,Y., Isono,Y., Nakamura,Y.,
            Nagahari,K., Murakami,K., Yasuda,T., Iwayanagi,T., Wagatsuma,M.,
            Shiratori,A., Sudo,H., Hosoiri,T., Kaku,Y., Kodaira,H., Kondo,H.,
            Sugawara,M., Takahashi,M., Kanda,K., Yokoi,T., Furuya,T.,
            Kikkawa,E., Omura,Y., Abe,K., Kamihara,K., Katsuta,N., Sato,K.,
            Tanikawa,M., Yamazaki,M., Ninomiya,K., Ishibashi,T., Yamashita,H.,
            Murakawa,K., Fujimori,K., Tanai,H., Kimata,M., Watanabe,M.,
            Hiraoka,S., Chiba,Y., Ishida,S., Ono,Y., Takiguchi,S., Watanabe,S.,
            Yosida,M., Hotuta,T., Kusano,J., Kanehori,K., Takahashi-Fujii,A.,
            Hara,H., Tanase,T.O., Nomura,Y., Togiya,S., Komai,F., Hara,R.,
            Takeuchi,K., Arita,M., Imose,N., Musashino,K., Yuuki,H., Oshima,A.,
            Sasaki,N., Aotsuka,S., Yoshikawa,Y., Matsunawa,H., Ichihara,T.,
            Shiohata,N., Sano,S., Moriya,S., Momiyama,H., Satoh,N., Takami,S.,
            Terashima,Y., Suzuki,O., Nakagawa,S., Senoh,A., Mizoguchi,H.,
            Goto,Y., Shimizu,F., Wakebe,H., Hishigaki,H., Watanabe,T.,
            Sugiyama,A., Takemoto,M., Kawakami,B., Yamazaki,M., Watanabe,K.,
            Kumagai,A., Itakura,S., Fukuzumi,Y., Fujimori,Y., Komiyama,M.,
            Tashiro,H., Tanigami,A., Fujiwara,T., Ono,T., Yamada,K., Fujii,Y.,
            Ozaki,K., Hirao,M., Ohmori,Y., Kawabata,A., Hikiji,T., Kobatake,N.,
            Inagaki,H., Ikema,Y., Okamoto,S., Okitani,R., Kawakami,T.,
            Noguchi,S., Itoh,T., Shigeta,K., Senba,T., Matsumura,K.,
            Nakajima,Y., Mizuno,T., Morinaga,M., Sasaki,M., Togashi,T.,
            Oyama,M., Hata,H., Watanabe,M., Komatsu,T., Mizushima-Sugano,J.,
            Satoh,T., Shirai,Y., Takahashi,Y., Nakagawa,K., Okumura,K.,
            Nagase,T., Nomura,N., Kikuchi,H., Masuho,Y., Yamashita,R.,
            Nakai,K., Yada,T., Nakamura,Y., Ohara,O., Isogai,T. and Sugano,S.
  TITLE     Complete sequencing and characterization of 21,243 full-length
            human cDNAs
  JOURNAL   Nat Genet 36 (1), 40-45 (2004)
   PUBMED   14702039
  REMARK    NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3; 4 AND 5),
            AND VARIANT GLU-93.;
            TISSUE=Pericardium, Placenta, and Tongue
REFERENCE   10 (residues 1 to 540)
  AUTHORS   Deloukas,P., Matthews,L.H., Ashurst,J., Burton,J., Gilbert,J.G.,
            Jones,M., Stavrides,G., Almeida,J.P., Babbage,A.K., Bagguley,C.L.,
            Bailey,J., Barlow,K.F., Bates,K.N., Beard,L.M., Beare,D.M.,
            Beasley,O.P., Bird,C.P., Blakey,S.E., Bridgeman,A.M., Brown,A.J.,
            Buck,D., Burrill,W., Butler,A.P., Carder,C., Carter,N.P.,
            Chapman,J.C., Clamp,M., Clark,G., Clark,L.N., Clark,S.Y.,
            Clee,C.M., Clegg,S., Cobley,V.E., Collier,R.E., Connor,R.,
            Corby,N.R., Coulson,A., Coville,G.J., Deadman,R., Dhami,P.,
            Dunn,M., Ellington,A.G., Frankland,J.A., Fraser,A., French,L.,
            Garner,P., Grafham,D.V., Griffiths,C., Griffiths,M.N., Gwilliam,R.,
            Hall,R.E., Hammond,S., Harley,J.L., Heath,P.D., Ho,S., Holden,J.L.,
            Howden,P.J., Huckle,E., Hunt,A.R., Hunt,S.E., Jekosch,K.,
            Johnson,C.M., Johnson,D., Kay,M.P., Kimberley,A.M., King,A.,
            Knights,A., Laird,G.K., Lawlor,S., Lehvaslaiho,M.H., Leversha,M.,
            Lloyd,C., Lloyd,D.M., Lovell,J.D., Marsh,V.L., Martin,S.L.,
            McConnachie,L.J., McLay,K., McMurray,A.A., Milne,S., Mistry,D.,
            Moore,M.J., Mullikin,J.C., Nickerson,T., Oliver,K., Parker,A.,
            Patel,R., Pearce,T.A., Peck,A.I., Phillimore,B.J.,
            Prathalingam,S.R., Plumb,R.W., Ramsay,H., Rice,C.M., Ross,M.T.,
            Scott,C.E., Sehra,H.K., Shownkeen,R., Sims,S., Skuce,C.D.,
            Smith,M.L., Soderlund,C., Steward,C.A., Sulston,J.E., Swann,M.,
            Sycamore,N., Taylor,R., Tee,L., Thomas,D.W., Thorpe,A., Tracey,A.,
            Tromans,A.C., Vaudin,M., Wall,M., Wallis,J.M., Whitehead,S.L.,
            Whittaker,P., Willey,D.L., Williams,L., Williams,S.A., Wilming,L.,
            Wray,P.W., Hubbard,T., Durbin,R.M., Bentley,D.R., Beck,S. and
            Rogers,J.
  TITLE     The DNA sequence and comparative analysis of human chromosome 20
  JOURNAL   Nature 414 (6866), 865-871 (2001)
   PUBMED   11780052
  REMARK    NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
REFERENCE   11 (residues 1 to 540)
  AUTHORS   Mural,R.J., Istrail,S., Sutton,G.G., Florea,L., Halpern,A.L.,
            Mobarry,C.M., Lippert,R., Walenz,B., Shatkay,H., Dew,I.,
            Miller,J.R., Flanigan,M.J., Edwards,N.J., Bolanos,R., Fasulo,D.,
            Halldorsson,B.V., Hannenhalli,S., Turner,R., Yooseph,S., Lu,F.,
            Nusskern,D.R., Shue,B.C., Zheng,X.H., Zhong,F., Delcher,A.L.,
            Huson,D.H., Kravitz,S.A., Mouchard,L., Reinert,K., Remington,K.A.,
            Clark,A.G., Waterman,M.S., Eichler,E.E., Adams,M.D.,
            Hunkapiller,M.W., Myers,E.W. and Venter,J.C.
  TITLE     Direct Submission
  JOURNAL   Submitted (??-SEP-2005) to the EMBL/GenBank/DDBJ databases
  REMARK    NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
REFERENCE   12 (residues 1 to 540)
  AUTHORS   Gerhard,D.S., Wagner,L., Feingold,E.A., Shenmen,C.M., Grouse,L.H.,
            Schuler,G., Klein,S.L., Old,S., Rasooly,R., Good,P., Guyer,M.,
            Peck,A.M., Derge,J.G., Lipman,D., Collins,F.S., Jang,W., Sherry,S.,
            Feolo,M., Misquitta,L., Lee,E., Rotmistrovsky,K., Greenhut,S.F.,
            Schaefer,C.F., Buetow,K., Bonner,T.I., Haussler,D., Kent,J.,
            Kiekhaus,M., Furey,T., Brent,M., Prange,C., Schreiber,K.,
            Shapiro,N., Bhat,N.K., Hopkins,R.F., Hsie,F., Driscoll,T.,
            Soares,M.B., Casavant,T.L., Scheetz,T.E., Brown-stein,M.J.,
            Usdin,T.B., Toshiyuki,S., Carninci,P., Piao,Y., Dudekula,D.B.,
            Ko,M.S., Kawakami,K., Suzuki,Y., Sugano,S., Gruber,C.E.,
            Smith,M.R., Simmons,B., Moore,T., Waterman,R., Johnson,S.L.,
            Ruan,Y., Wei,C.L., Mathavan,S., Gunaratne,P.H., Wu,J., Garcia,A.M.,
            Hulyk,S.W., Fuh,E., Yuan,Y., Sneed,A., Kowis,C., Hodgson,A.,
            Muzny,D.M., McPherson,J., Gibbs,R.A., Fahey,J., Helton,E.,
            Ketteman,M., Madan,A., Rodrigues,S., Sanchez,A., Whiting,M.,
            Madari,A., Young,A.C., Wetherby,K.D., Granite,S.J., Kwong,P.N.,
            Brinkley,C.P., Pearson,R.L., Bouffard,G.G., Blakesly,R.W.,
            Green,E.D., Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J.,
            Myers,R.M., Butterfield,Y.S., Griffith,M., Griffith,O.L.,
            Krzywinski,M.I., Liao,N., Morin,R., Palmquist,D., Petrescu,A.S.,
            Skalska,U., Smailus,D.E., Stott,J.M., Schnerch,A., Schein,J.E.,
            Jones,S.J., Holt,R.A., Baross,A., Marra,M.A., Clifton,S.,
            Makowski,K.A., Bosak,S. and Malek,J.
  CONSRTM   MGC Project Team
  TITLE     The status, quality, and expansion of the NIH full-length cDNA
            project: the Mammalian Gene Collection (MGC)
  JOURNAL   Genome Res 14 (10B), 2121-2127 (2004)
   PUBMED   15489334
  REMARK    NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS GLU-93;
            LYS-198 AND PHE-409.;
            TISSUE=Brain
            Erratum:[Genome Res. 2006 Jun;16(6):804. Morrin, Ryan [corrected to
            Morin, Ryan]]
REFERENCE   13 (residues 1 to 540)
  AUTHORS   Li,X.D., Sun,L., Seth,R.B., Pineda,G. and Chen,Z.J.
  TITLE     Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral
            signaling protein off the mitochondria to evade innate immunity
  JOURNAL   Proc Natl Acad Sci U S A 102 (49), 17717-17722 (2005)
   PUBMED   16301520
  REMARK    INTERACTION WITH HCV NS3/4A PROTEASE (MICROBIAL INFECTION),
            MUTAGENESIS OF CYS-435; CYS-452 AND CYS-508, AND PROTEOLYTIC
            CLEAVAGE (MICROBIAL INFECTION).
REFERENCE   14 (residues 1 to 540)
  AUTHORS   Komuro,A. and Horvath,C.M.
  TITLE     RNA- and virus-independent inhibition of antiviral signaling by RNA
            helicase LGP2
  JOURNAL   J Virol 80 (24), 12332-12342 (2006)
   PUBMED   17020950
  REMARK    INTERACTION WITH DHX58/LGP2 AND IKBKE.
REFERENCE   15 (residues 1 to 540)
  AUTHORS   Beausoleil,S.A., Villen,J., Gerber,S.A., Rush,J. and Gygi,S.P.
  TITLE     A probability-based approach for high-throughput protein
            phosphorylation analysis and site localization
  JOURNAL   Nat Biotechnol 24 (10), 1285-1292 (2006)
   PUBMED   16964243
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222, AND
            IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Cervix carcinoma
REFERENCE   16 (residues 1 to 540)
  AUTHORS   Chen,Z., Benureau,Y., Rijnbrand,R., Yi,J., Wang,T., Warter,L.,
            Lanford,R.E., Weinman,S.A., Lemon,S.M., Martin,A. and Li,K.
  TITLE     GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of
            the adaptor protein MAVS
  JOURNAL   J Virol 81 (2), 964-976 (2007)
   PUBMED   17093192
  REMARK    INTERACTION WITH HEPATITIS GB VIRUS B NS3/4A PROTEASE (MICROBIAL
            INFECTION), CLEAVAGE SITE, AND MUTAGENESIS OF CYS-508.
REFERENCE   17 (residues 1 to 540)
  AUTHORS   Yang,Y., Liang,Y., Qu,L., Chen,Z., Yi,M., Li,K. and Lemon,S.M.
  TITLE     Disruption of innate immunity due to mitochondrial targeting of a
            picornaviral protease precursor
  JOURNAL   Proc Natl Acad Sci U S A 104 (17), 7253-7258 (2007)
   PUBMED   17438296
  REMARK    CLEAVAGE BY HAV PROTEIN 3CD (MICROBIAL INFECTION), CLEAVAGE SITE,
            AND MUTAGENESIS OF GLN-427 AND GLU-463.
REFERENCE   18 (residues 1 to 540)
  AUTHORS   Arimoto,K., Takahashi,H., Hishiki,T., Konishi,H., Fujita,T. and
            Shimotohno,K.
  TITLE     Negative regulation of the RIG-I signaling by the ubiquitin ligase
            RNF125
  JOURNAL   Proc Natl Acad Sci U S A 104 (18), 7500-7505 (2007)
   PUBMED   17460044
  REMARK    UBIQUITINATION.
REFERENCE   19 (residues 1 to 540)
  AUTHORS   Diao,F., Li,S., Tian,Y., Zhang,M., Xu,L.G., Zhang,Y., Wang,R.P.,
            Chen,D., Zhai,Z., Zhong,B., Tien,P. and Shu,H.B.
  TITLE     Negative regulation of MDA5- but not RIG-I-mediated innate
            antiviral signaling by the dihydroxyacetone kinase
  JOURNAL   Proc Natl Acad Sci U S A 104 (28), 11706-11711 (2007)
   PUBMED   17600090
  REMARK    INTERACTION WITH IFIH1.
REFERENCE   20 (residues 1 to 540)
  AUTHORS   Jounai,N., Takeshita,F., Kobiyama,K., Sawano,A., Miyawaki,A.,
            Xin,K.Q., Ishii,K.J., Kawai,T., Akira,S., Suzuki,K. and Okuda,K.
  TITLE     The Atg5 Atg12 conjugate associates with innate antiviral immune
            responses
  JOURNAL   Proc Natl Acad Sci U S A 104 (35), 14050-14055 (2007)
   PUBMED   17709747
  REMARK    INTERACTION WITH ATG5 AND ATG12, SUBCELLULAR LOCATION, AND
            MUTAGENESIS OF THR-54.
REFERENCE   21 (residues 1 to 540)
  AUTHORS   Friedman,C.S., O'Donnell,M.A., Legarda-Addison,D., Ng,A.,
            Cardenas,W.B., Yount,J.S., Moran,T.M., Basler,C.F., Komuro,A.,
            Horvath,C.M., Xavier,R. and Ting,A.T.
  TITLE     The tumour suppressor CYLD is a negative regulator of
            RIG-I-mediated antiviral response
  JOURNAL   EMBO Rep 9 (9), 930-936 (2008)
   PUBMED   18636086
  REMARK    INTERACTION WITH CYLD.
REFERENCE   22 (residues 1 to 540)
  AUTHORS   Zahedi,R.P., Lewandrowski,U., Wiesner,J., Wortelkamp,S.,
            Moebius,J., Schutz,C., Walter,U., Gambaryan,S. and Sickmann,A.
  TITLE     Phosphoproteome of resting human platelets
  JOURNAL   J Proteome Res 7 (2), 526-534 (2008)
   PUBMED   18088087
  REMARK    IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Platelet
REFERENCE   23 (residues 1 to 540)
  AUTHORS   Daub,H., Olsen,J.V., Bairlein,M., Gnad,F., Oppermann,F.S.,
            Korner,R., Greff,Z., Keri,G., Stemmann,O. and Mann,M.
  TITLE     Kinase-selective enrichment enables quantitative phosphoproteomics
            of the kinome across the cell cycle
  JOURNAL   Mol Cell 31 (3), 438-448 (2008)
   PUBMED   18691976
  REMARK    IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Cervix carcinoma
REFERENCE   24 (residues 1 to 540)
  AUTHORS   Moore,C.B., Bergstralh,D.T., Duncan,J.A., Lei,Y., Morrison,T.E.,
            Zimmermann,A.G., Accavitti-Loper,M.A., Madden,V.J., Sun,L., Ye,Z.,
            Lich,J.D., Heise,M.T., Chen,Z. and Ting,J.P.
  TITLE     NLRX1 is a regulator of mitochondrial antiviral immunity
  JOURNAL   Nature 451 (7178), 573-577 (2008)
   PUBMED   18200010
  REMARK    INTERACTION WITH NLRX1.
REFERENCE   25 (residues 1 to 540)
  AUTHORS   Dephoure,N., Zhou,C., Villen,J., Beausoleil,S.A., Bakalarski,C.E.,
            Elledge,S.J. and Gygi,S.P.
  TITLE     A quantitative atlas of mitotic phosphorylation
  JOURNAL   Proc Natl Acad Sci U S A 105 (31), 10762-10767 (2008)
   PUBMED   18669648
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-152; SER-157;
            SER-165; SER-222; SER-233; THR-234 AND SER-258, AND IDENTIFICATION
            BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Cervix carcinoma
REFERENCE   26 (residues 1 to 540)
  AUTHORS   Gauci,S., Helbig,A.O., Slijper,M., Krijgsveld,J., Heck,A.J. and
            Mohammed,S.
  TITLE     Lys-N and trypsin cover complementary parts of the phosphoproteome
            in a refined SCX-based approach
  JOURNAL   Anal Chem 81 (11), 4493-4501 (2009)
   PUBMED   19413330
  REMARK    IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
REFERENCE   27 (residues 1 to 540)
  AUTHORS   Chiu,Y.H., Macmillan,J.B. and Chen,Z.J.
  TITLE     RNA polymerase III detects cytosolic DNA and induces type I
            interferons through the RIG-I pathway
  JOURNAL   Cell 138 (3), 576-591 (2009)
   PUBMED   19631370
  REMARK    FUNCTION.
REFERENCE   28 (residues 1 to 540)
  AUTHORS   Johnsen,I.B., Nguyen,T.T., Bergstroem,B., Fitzgerald,K.A. and
            Anthonsen,M.W.
  TITLE     The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible
            gene I)-elicited antiviral signaling
  JOURNAL   J Biol Chem 284 (28), 19122-19131 (2009)
   PUBMED   19419966
  REMARK    INTERACTION WITH SRC.
REFERENCE   29 (residues 1 to 540)
  AUTHORS   Jia,Y., Song,T., Wei,C., Ni,C., Zheng,Z., Xu,Q., Ma,H., Li,L.,
            Zhang,Y., He,X., Xu,Y., Shi,W. and Zhong,H.
  TITLE     Negative regulation of MAVS-mediated innate immune response by
            PSMA7
  JOURNAL   J Immunol 183 (7), 4241-4248 (2009)
   PUBMED   19734229
  REMARK    INTERACTION WITH PSMA7.
REFERENCE   30 (residues 1 to 540)
  AUTHORS   You,F., Sun,H., Zhou,X., Sun,W., Liang,S., Zhai,Z. and Jiang,Z.
  TITLE     PCBP2 mediates degradation of the adaptor MAVS via the HECT
            ubiquitin ligase AIP4
  JOURNAL   Nat Immunol 10 (12), 1300-1308 (2009)
   PUBMED   19881509
  REMARK    INTERACTION WITH PCBP2, AND UBIQUITINATION BY ITCH.
REFERENCE   31 (residues 1 to 540)
  AUTHORS   Xu,L., Xiao,N., Liu,F., Ren,H. and Gu,J.
  TITLE     Inhibition of RIG-I and MDA5-dependent antiviral response by gC1qR
            at mitochondria
  JOURNAL   Proc Natl Acad Sci U S A 106 (5), 1530-1535 (2009)
   PUBMED   19164550
  REMARK    INTERACTION WITH C1QBP.
REFERENCE   32 (residues 1 to 540)
  AUTHORS   Li,Y., Li,C., Xue,P., Zhong,B., Mao,A.P., Ran,Y., Chen,H.,
            Wang,Y.Y., Yang,F. and Shu,H.B.
  TITLE     ISG56 is a negative-feedback regulator of virus-triggered signaling
            and cellular antiviral response
  JOURNAL   Proc Natl Acad Sci U S A 106 (19), 7945-7950 (2009)
   PUBMED   19416887
  REMARK    INTERACTION WITH STING1.
REFERENCE   33 (residues 1 to 540)
  AUTHORS   Mayya,V., Lundgren,D.H., Hwang,S.I., Rezaul,K., Wu,L., Eng,J.K.,
            Rodionov,V. and Han,D.K.
  TITLE     Quantitative phosphoproteomic analysis of T cell receptor signaling
            reveals system-wide modulation of protein-protein interactions
  JOURNAL   Sci Signal 2 (84), ra46 (2009)
   PUBMED   19690332
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-152 AND SER-165, AND
            IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Leukemic T-cell
            Publication Status: Online-Only
REFERENCE   34 (residues 1 to 540)
  AUTHORS   Dixit,E., Boulant,S., Zhang,Y., Lee,A.S., Odendall,C., Shum,B.,
            Hacohen,N., Chen,Z.J., Whelan,S.P., Fransen,M., Nibert,M.L.,
            Superti-Furga,G. and Kagan,J.C.
  TITLE     Peroxisomes are signaling platforms for antiviral innate immunity
  JOURNAL   Cell 141 (4), 668-681 (2010)
   PUBMED   20451243
  REMARK    FUNCTION, AND SUBCELLULAR LOCATION.
REFERENCE   35 (residues 1 to 540)
  AUTHORS   Oshiumi,H., Sakai,K., Matsumoto,M. and Seya,T.
  TITLE     DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to
            up-regulate IFN-beta-inducing potential
  JOURNAL   Eur J Immunol 40 (4), 940-948 (2010)
   PUBMED   20127681
  REMARK    FUNCTION, INTERACTION WITH DDX3X, AND SUBCELLULAR LOCATION.
REFERENCE   36 (residues 1 to 540)
  AUTHORS   Oshiumi,H., Ikeda,M., Matsumoto,M., Watanabe,A., Takeuchi,O.,
            Akira,S., Kato,N., Shimotohno,K. and Seya,T.
  TITLE     Hepatitis C virus core protein abrogates the DDX3 function that
            enhances IPS-1-mediated IFN-beta induction
  JOURNAL   PLoS One 5 (12), e14258 (2010)
   PUBMED   21170385
  REMARK    FUNCTION, INTERACTION WITH DDX3X, AND SUBCELLULAR LOCATION.
            Publication Status: Online-Only
REFERENCE   37 (residues 1 to 540)
  AUTHORS   Olsen,J.V., Vermeulen,M., Santamaria,A., Kumar,C., Miller,M.L.,
            Jensen,L.J., Gnad,F., Cox,J., Jensen,T.S., Nigg,E.A., Brunak,S. and
            Mann,M.
  TITLE     Quantitative phosphoproteomics reveals widespread full
            phosphorylation site occupancy during mitosis
  JOURNAL   Sci Signal 3 (104), ra3 (2010)
   PUBMED   20068231
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-253 AND SER-258, AND
            IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Cervix carcinoma
            Publication Status: Online-Only
REFERENCE   38 (residues 1 to 540)
  AUTHORS   Burkard,T.R., Planyavsky,M., Kaupe,I., Breitwieser,F.P.,
            Burckstummer,T., Bennett,K.L., Superti-Furga,G. and Colinge,J.
  TITLE     Initial characterization of the human central proteome
  JOURNAL   BMC Syst Biol 5, 17 (2011)
   PUBMED   21269460
  REMARK    IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
            Publication Status: Online-Only
REFERENCE   39 (residues 1 to 540)
  AUTHORS   Mukherjee,A., Morosky,S.A., Delorme-Axford,E., Dybdahl-Sissoko,N.,
            Oberste,M.S., Wang,T. and Coyne,C.B.
  TITLE     The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate
            host type I interferon and apoptotic signaling
  JOURNAL   PLoS Pathog 7 (3), e1001311 (2011)
   PUBMED   21436888
  REMARK    PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION), AND MUTAGENESIS OF
            GLN-148.
REFERENCE   40 (residues 1 to 540)
  AUTHORS   Liu,X.Y., Chen,W., Wei,B., Shan,Y.F. and Wang,C.
  TITLE     IFN-induced TPR protein IFIT3 potentiates antiviral signaling by
            bridging MAVS and TBK1
  JOURNAL   J Immunol 187 (5), 2559-2568 (2011)
   PUBMED   21813773
  REMARK    INTERACTION WITH IFIT3 AND TBK1.
REFERENCE   41 (residues 1 to 540)
  AUTHORS   Wang,Y., Tong,X. and Ye,X.
  TITLE     Ndfip1 negatively regulates RIG-I-dependent immune signaling by
            enhancing E3 ligase Smurf1-mediated MAVS degradation
  JOURNAL   J Immunol 189 (11), 5304-5313 (2012)
   PUBMED   23087404
  REMARK    FUNCTION, INTERACTION WITH NDFIP1 AND SMURF1, AND UBIQUITINATION BY
            SMURF1.
REFERENCE   42 (residues 1 to 540)
  AUTHORS   Boyapalle,S., Wong,T., Garay,J., Teng,M., San Juan-Vergara,H.,
            Mohapatra,S. and Mohapatra,S.
  TITLE     Respiratory syncytial virus NS1 protein colocalizes with
            mitochondrial antiviral signaling protein MAVS following infection
  JOURNAL   PLoS One 7 (2), e29386 (2012)
   PUBMED   22383950
  REMARK    INTERACTION WITH HRSV NS1 (MICROBIAL INFECTION).
REFERENCE   43 (residues 1 to 540)
  AUTHORS   Menning,M. and Kufer,T.A.
  TITLE     A role for the Ankyrin repeat containing protein Ankrd17 in Nod1-
            and Nod2-mediated inflammatory responses
  JOURNAL   FEBS Lett 587 (14), 2137-2142 (2013)
   PUBMED   23711367
  REMARK    INTERACTION WITH ANKRD17.
REFERENCE   44 (residues 1 to 540)
  AUTHORS   Jenkins,K., Khoo,J.J., Sadler,A., Piganis,R., Wang,D., Borg,N.A.,
            Hjerrild,K., Gould,J., Thomas,B.J., Nagley,P., Hertzog,P.J. and
            Mansell,A.
  TITLE     Mitochondrially localised MUL1 is a novel modulator of antiviral
            signaling
  JOURNAL   Immunol Cell Biol 91 (4), 321-330 (2013)
   PUBMED   23399697
  REMARK    INTERACTION WITH MUL1.
REFERENCE   45 (residues 1 to 540)
  AUTHORS   Wang,P., Yang,L., Cheng,G., Yang,G., Xu,Z., You,F., Sun,Q., Lin,R.,
            Fikrig,E. and Sutton,R.E.
  TITLE     UBXN1 interferes with Rig-I-like receptor-mediated antiviral immune
            response by targeting MAVS
  JOURNAL   Cell Rep 3 (4), 1057-1070 (2013)
   PUBMED   23545497
  REMARK    INTERACTION WITH UBXN1.
REFERENCE   46 (residues 1 to 540)
  AUTHORS   Zhou,H., Di Palma,S., Preisinger,C., Peng,M., Polat,A.N., Heck,A.J.
            and Mohammed,S.
  TITLE     Toward a comprehensive characterization of a human cancer cell
            phosphoproteome
  JOURNAL   J Proteome Res 12 (1), 260-271 (2013)
   PUBMED   23186163
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222, AND
            IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Cervix carcinoma, and Erythroleukemia
REFERENCE   47 (residues 1 to 540)
  AUTHORS   Bian,Y., Song,C., Cheng,K., Dong,M., Wang,F., Huang,J., Sun,D.,
            Wang,L., Ye,M. and Zou,H.
  TITLE     An enzyme assisted RP-RPLC approach for in-depth analysis of human
            liver phosphoproteome
  JOURNAL   J Proteomics 96, 253-262 (2014)
   PUBMED   24275569
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-152; SER-165;
            SER-180; SER-188; THR-215 AND SER-222, AND IDENTIFICATION BY MASS
            SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Liver
REFERENCE   48 (residues 1 to 540)
  AUTHORS   Feng,Q., Langereis,M.A., Lork,M., Nguyen,M., Hato,S.V., Lanke,K.,
            Emdad,L., Bhoopathi,P., Fisher,P.B., Lloyd,R.E. and van
            Kuppeveld,F.J.
  TITLE     Enterovirus 2Apro targets MDA5 and MAVS in infected cells
  JOURNAL   J Virol 88 (6), 3369-3378 (2014)
   PUBMED   24390337
  REMARK    PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION).
REFERENCE   49 (residues 1 to 540)
  AUTHORS   Shi,C.S., Qi,H.Y., Boularan,C., Huang,N.N., Abu-Asab,M.,
            Shelhamer,J.H. and Kehrl,J.H.
  TITLE     SARS-coronavirus open reading frame-9b suppresses innate immunity
            by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome
  JOURNAL   J Immunol 193 (6), 3080-3089 (2014)
   PUBMED   25135833
  REMARK    INTERACTION WITH SARS-COV VIRUS PROTEIN ORF9B (MICROBIAL
            INFECTION), AND SUBCELLULAR LOCATION.
REFERENCE   50 (residues 1 to 540)
  AUTHORS   Liu,S., Cai,X., Wu,J., Cong,Q., Chen,X., Li,T., Du,F., Ren,J.,
            Wu,Y.T., Grishin,N.V. and Chen,Z.J.
  TITLE     Phosphorylation of innate immune adaptor proteins MAVS, STING, and
            TRIF induces IRF3 activation
  JOURNAL   Science 347 (6227), aaa2630 (2015)
   PUBMED   25636800
  REMARK    FUNCTION, DOMAIN, INTERACTION WITH IRF3, PHOSPHORYLATION AT
            SER-442, UBIQUITINATION, AND MUTAGENESIS OF SER-442.
REFERENCE   51 (residues 1 to 540)
  AUTHORS   Vaca Jacome,A.S., Rabilloud,T., Schaeffer-Reiss,C., Rompais,M.,
            Ayoub,D., Lane,L., Bairoch,A., Van Dorsselaer,A. and Carapito,C.
  TITLE     N-terminome analysis of the human mitochondrial proteome
  JOURNAL   Proteomics 15 (14), 2519-2524 (2015)
   PUBMED   25944712
  REMARK    IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
REFERENCE   52 (residues 1 to 540)
  AUTHORS   Gu,L., Fullam,A., McCormack,N., Hohn,Y. and Schroder,M.
  TITLE     DDX3 directly regulates TRAF3 ubiquitination and acts as a scaffold
            to co-ordinate assembly of signalling complexes downstream from
            MAVS
  JOURNAL   Biochem J 474 (4), 571-587 (2017)
   PUBMED   27980081
  REMARK    INTERACTION WITH DDX3X AND TRAF3.
REFERENCE   53 (residues 1 to 540)
  AUTHORS   Ju,L.G., Zhu,Y., Lei,P.J., Yan,D., Zhu,K., Wang,X., Li,Q.L.,
            Li,X.J., Chen,J.W., Li,L.Y. and Wu,M.
  TITLE     TTLL12 Inhibits the Activation of Cellular Antiviral Signaling
            through Interaction with VISA/MAVS
  JOURNAL   J Immunol 198 (3), 1274-1284 (2017)
   PUBMED   28011935
  REMARK    INTERACTION WITH TTLL12; TBK1 AND IKBKE.
REFERENCE   54 (residues 1 to 540)
  AUTHORS   Qian,S., Fan,W., Liu,T., Wu,M., Zhang,H., Cui,X., Zhou,Y., Hu,J.,
            Wei,S., Chen,H., Li,X. and Qian,P.
  TITLE     Seneca Valley Virus Suppresses Host Type I Interferon Production by
            Targeting Adaptor Proteins MAVS, TRIF, and TANK for Cleavage
  JOURNAL   J Virol 91 (16), e00823-17 (2017)
   PUBMED   28566380
  REMARK    INTERACTION WITH SENECA VALLEY VIRUS PROTEASE 3C (MICROBIAL
            INFECTION), PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION), AND
            MUTAGENESIS OF GLN-148; GLN-159; GLN-162; GLN-196 AND GLN-198.
            Publication Status: Online-Only
REFERENCE   55 (residues 1 to 540)
  AUTHORS   Wang,B., Xi,X., Lei,X., Zhang,X., Cui,S., Wang,J., Jin,Q. and
            Zhao,Z.
  TITLE     Correction: Enterovirus 71 Protease 2Apro Targets MAVS to Inhibit
            Anti-Viral Type I Interferon Responses
  JOURNAL   PLoS Pathog 13 (3), e1006243 (2017)
   PUBMED   28253362
  REMARK    PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION).
            Correction to:[PLoS Pathog. 2013 Mar;9(3):e1003231. PMID: 23555247]
            Publication Status: Online-Only
REFERENCE   56 (residues 1 to 540)
  AUTHORS   Nie,Y., Ran,Y., Zhang,H.Y., Huang,Z.F., Pan,Z.Y., Wang,S.Y. and
            Wang,Y.Y.
  TITLE     GPATCH3 negatively regulates RLR-mediated innate antiviral
            responses by disrupting the assembly of VISA signalosome
  JOURNAL   PLoS Pathog 13 (4), e1006328 (2017)
   PUBMED   28414768
  REMARK    INTERACTION WITH GPATCH3.
            Publication Status: Online-Only
REFERENCE   57 (residues 1 to 540)
  AUTHORS   Yoshinaka,T., Kosako,H., Yoshizumi,T., Furukawa,R., Hirano,Y.,
            Kuge,O., Tamada,T. and Koshiba,T.
  TITLE     Structural Basis of Mitochondrial Scaffolds by Prohibitin
            Complexes: Insight into a Role of the Coiled-Coil Region
  JOURNAL   iScience 19, 1065-1078 (2019)
   PUBMED   31522117
  REMARK    INTERACTION WITH CLPB.
REFERENCE   58 (residues 1 to 540)
  AUTHORS   Zhu,W., Li,J., Zhang,R., Cai,Y., Wang,C., Qi,S., Chen,S., Liang,X.,
            Qi,N. and Hou,F.
  TITLE     TRAF3IP3 mediates the recruitment of TRAF3 to MAVS for antiviral
            innate immunity
  JOURNAL   EMBO J 38 (18), e102075 (2019)
   PUBMED   31390091
  REMARK    INTERACTION WITH TRAF3IP3.
REFERENCE   59 (residues 1 to 540)
  AUTHORS   Xu,H., He,X., Zheng,H., Huang,L.J., Hou,F., Yu,Z., de la Cruz,M.J.,
            Borkowski,B., Zhang,X., Chen,Z.J. and Jiang,Q.X.
  TITLE     Structural basis for the prion-like MAVS filaments in antiviral
            innate immunity
  JOURNAL   Elife 3, e01489 (2014)
   PUBMED   24569476
  REMARK    STRUCTURE BY ELECTRON MICROSCOPY (9.6 ANGSTROMS) OF 3-93, SUBUNIT,
            AND MUTAGENESIS OF GLU-26 AND TRP-56.
            Erratum:[Elife. 2015;4. doi: 10.7554/eLife.07546. PMID: 26314863]
            Publication Status: Online-Only
REFERENCE   60 (residues 1 to 540)
  AUTHORS   Wu,B., Peisley,A., Tetrault,D., Li,Z., Egelman,E.H., Magor,K.E.,
            Walz,T., Penczek,P.A. and Hur,S.
  TITLE     Molecular imprinting as a signal-activation mechanism of the viral
            RNA sensor RIG-I
  JOURNAL   Mol Cell 55 (4), 511-523 (2014)
   PUBMED   25018021
  REMARK    X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 1-99 IN COMPLEX WITH
            DDX58/RIG-I, STRUCTURE BY ELECTRON MICROSCOPY (3.64 ANGSTROMS) OF
            1-97, AND SUBUNIT.
REFERENCE   61 (residues 1 to 540)
  AUTHORS   Zhao,B., Shu,C., Gao,X., Sankaran,B., Du,F., Shelton,C.L.,
            Herr,A.B., Ji,J.Y. and Li,P.
  TITLE     Structural basis for concerted recruitment and activation of IRF-3
            by innate immune adaptor proteins
  JOURNAL   Proc Natl Acad Sci U S A 113 (24), E3403-E3412 (2016)
   PUBMED   27302953
  REMARK    X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 433-450 IN COMPLEX WITH
            IRF3, INTERACTION WITH IRF3, PHOSPHORYLATION AT SER-442, AND
            MUTAGENESIS OF SER-442.
COMMENT     On or before May 26, 2009 this sequence version replaced
            gi:121941172, gi:74727637, gi:74745383.
            [FUNCTION] Required for innate immune defense against viruses
            (PubMed:16125763, PubMed:16127453, PubMed:16153868,
            PubMed:16177806, PubMed:19631370, PubMed:20451243, PubMed:23087404,
            PubMed:20127681, PubMed:21170385). Acts downstream of DHX33,
            DDX58/RIG-I and IFIH1/MDA5, which detect intracellular dsRNA
            produced during viral replication, to coordinate pathways leading
            to the activation of NF-kappa-B, IRF3 and IRF7, and to the
            subsequent induction of antiviral cytokines such as IFN-beta and
            RANTES (CCL5) (PubMed:16125763, PubMed:16127453, PubMed:16153868,
            PubMed:16177806, PubMed:19631370, PubMed:20451243, PubMed:23087404,
            PubMed:25636800, PubMed:20127681, PubMed:21170385). Peroxisomal and
            mitochondrial MAVS act sequentially to create an antiviral cellular
            state (PubMed:20451243). Upon viral infection, peroxisomal MAVS
            induces the rapid interferon-independent expression of defense
            factors that provide short-term protection, whereas mitochondrial
            MAVS activates an interferon-dependent signaling pathway with
            delayed kinetics, which amplifies and stabilizes the antiviral
            response (PubMed:20451243). May activate the same pathways
            following detection of extracellular dsRNA by TLR3
            (PubMed:16153868). May protect cells from apoptosis
            (PubMed:16125763). {ECO:0000269|PubMed:16125763,
            ECO:0000269|PubMed:16127453, ECO:0000269|PubMed:16153868,
            ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:19631370,
            ECO:0000269|PubMed:20127681, ECO:0000269|PubMed:20451243,
            ECO:0000269|PubMed:21170385, ECO:0000269|PubMed:23087404,
            ECO:0000269|PubMed:25636800}.
            [SUBUNIT] Self-associates and polymerizes (via CARD domains) to
            form 400 nM long three-stranded helical filaments on mitochondria,
            filament nucleation requires interaction with DDX58/RIG-I whose
            CARD domains act as a template for filament assembly
            (PubMed:24569476, PubMed:25018021). Interacts with DDX58/RIG-I,
            IFIH1/MDA5, TRAF2, TRAF6 and C1QBP (PubMed:16125763,
            PubMed:16127453, PubMed:17600090). May interact with FADD, RIPK1,
            CHUK and IKBKB (PubMed:16153868, PubMed:16177806, PubMed:16127453).
            Interacts (when phosphorylated) with IRF3; following activation and
            phosphorylation on the pLxIS motif by TBK1, recruits IRF3
            (PubMed:25636800, PubMed:27302953). Interacts with NLRX1
            (PubMed:18200010). Interaction with NLRX1 requires the CARD domain
            (PubMed:18200010). Interacts with PSMA7 (PubMed:19734229).
            Interacts with TRAFD1 (By similarity). Interacts (via C-terminus)
            with PCBP2 in a complex containing MAVS/IPS1, PCBP2 and ITCH
            (PubMed:19881509). Interacts with CYLD (PubMed:18636086). Interacts
            with SRC (PubMed:19419966). Interacts with DHX58/LGP2 and IKBKE
            (PubMed:16177806, PubMed:17020950, PubMed:28011935). Interacts with
            STING1 (PubMed:19416887). Interacts with IFIT3 (via N-terminus)
            (PubMed:21813773). Interacts with TBK1 only in the presence of
            IFIT3 (PubMed:21813773, PubMed:28011935). Interacts with TTLL12;
            the interaction prevents MAVS binding to TBK1 and IKBKE
            (PubMed:28011935). Interacts with MUL1 (PubMed:23399697). Interacts
            with ANKRD17 (PubMed:23711367). Interacts with NDFIP1
            (PubMed:23087404). Interacts with SMURF1; the interaction is
            mediated by NDFIP1 and leads to MAVS ubiquitination and degradation
            (PubMed:23087404). Interacts with UBXN1; this interaction inhibits
            MAVS-mediated antiviral pathway (PubMed:23545497). Interacts (via
            C-terminus) with GPATCH3; the interaction is markedly increased
            upon viral infection (PubMed:28414768). Directly interacts (via
            CARD domain) with ATG5 and ATG12, either as ATG5 and ATG12 monomers
            or as ATG12-ATG5 conjugates (PubMed:17709747). Interacts with DHX33
            (via the helicase C-terminal domain) (By similarity). Interacts
            with DDX3X (via C-terminus); this interaction occurs rapidly, but
            transiently after Sendai virus infection (PubMed:20127681,
            PubMed:21170385, PubMed:27980081). The interaction with DDX3X
            potentiates MAVS-mediated IFNB induction (PubMed:20127681).
            Conversely inhibition of this interaction, for instance by HCV core
            protein, prevents MAVS-mediated IFNB induction (PubMed:21170385).
            Transiently interacts with TRAF3 early during Sendai virus
            infection (PubMed:27980081). Interacts with CLPB; the interaction
            is enhanced by Sendai virus infection (PubMed:31522117). Interacts
            with TRAF3IP3 (PubMed:31390091). {ECO:0000250,
            ECO:0000250|UniProtKB:Q8VCF0, ECO:0000269|PubMed:16125763,
            ECO:0000269|PubMed:16127453, ECO:0000269|PubMed:16153868,
            ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:17020950,
            ECO:0000269|PubMed:17600090, ECO:0000269|PubMed:17709747,
            ECO:0000269|PubMed:18200010, ECO:0000269|PubMed:18636086,
            ECO:0000269|PubMed:19164550, ECO:0000269|PubMed:19416887,
            ECO:0000269|PubMed:19419966, ECO:0000269|PubMed:19734229,
            ECO:0000269|PubMed:19881509, ECO:0000269|PubMed:20127681,
            ECO:0000269|PubMed:21170385, ECO:0000269|PubMed:21813773,
            ECO:0000269|PubMed:23087404, ECO:0000269|PubMed:23399697,
            ECO:0000269|PubMed:23545497, ECO:0000269|PubMed:23711367,
            ECO:0000269|PubMed:24569476, ECO:0000269|PubMed:25018021,
            ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:27302953,
            ECO:0000269|PubMed:27980081, ECO:0000269|PubMed:28011935,
            ECO:0000269|PubMed:28414768, ECO:0000269|PubMed:31390091,
            ECO:0000269|PubMed:31522117}.
            [SUBUNIT] (Microbial infection) Interacts with hepatitis C virus
            (HCV) NS3/4A protease; this interaction leads to MAVS cleavage,
            thereby preventing the establishment of an antiviral state.
            {ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:16301520}.
            [SUBUNIT] (Microbial infection) Interacts with hepatitis GB virus B
            NS3/4A protease; this interaction leads to MAVS cleavage.
            {ECO:0000269|PubMed:17093192}.
            [SUBUNIT] (Microbial infection) Interacts with human respiratory
            syncytial virus/HRSV protein NS1; this interaction disrupts MAVS
            binding to DDX58/RIG-I. {ECO:0000269|PubMed:22383950}.
            [SUBUNIT] (Microbial infection) Interacts with Seneca Valley virus
            protease 3C; this interaction allows the cleavage of MAVS and
            subsequent suppression of host innate immunity.
            {ECO:0000269|PubMed:28566380}.
            [SUBUNIT] (Microbial infection) Interacts with SARS-CoV virus
            protein ORF9b; this interaction mediates MAVS proteasomal
            degradation. {ECO:0000269|PubMed:25135833}.
            [INTERACTION] Q7Z434; P00519: ABL1; NbExp=6; IntAct=EBI-995373,
            EBI-375543; Q7Z434; P46379: BAG6; NbExp=2; IntAct=EBI-995373,
            EBI-347552; Q7Z434; Q07021: C1QBP; NbExp=5; IntAct=EBI-995373,
            EBI-347528; Q7Z434; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-995373,
            EBI-739580; Q7Z434; O00571: DDX3X; NbExp=4; IntAct=EBI-995373,
            EBI-353779; Q7Z434; O95786: DDX58; NbExp=13; IntAct=EBI-995373,
            EBI-995350; Q7Z434; Q9BYX4: IFIH1; NbExp=5; IntAct=EBI-995373,
            EBI-6115771; Q7Z434; Q14164: IKBKE; NbExp=4; IntAct=EBI-995373,
            EBI-307369; Q7Z434; Q13568: IRF5; NbExp=2; IntAct=EBI-995373,
            EBI-3931258; Q7Z434; Q9Y2W7: KCNIP3; NbExp=3; IntAct=EBI-995373,
            EBI-751501; Q7Z434; Q8IWA4: MFN1; NbExp=2; IntAct=EBI-995373,
            EBI-1048197; Q7Z434; Q96P20: NLRP3; NbExp=4; IntAct=EBI-995373,
            EBI-6253230; Q7Z434; Q9Y6K5: OAS3; NbExp=2; IntAct=EBI-995373,
            EBI-6115729; Q7Z434; O43353: RIPK2; NbExp=3; IntAct=EBI-995373,
            EBI-358522; Q7Z434; P42224: STAT1; NbExp=3; IntAct=EBI-995373,
            EBI-1057697; Q7Z434; Q86WV6: STING1; NbExp=8; IntAct=EBI-995373,
            EBI-2800345; Q7Z434; Q9UHD2: TBK1; NbExp=2; IntAct=EBI-995373,
            EBI-356402; Q7Z434; Q12933: TRAF2; NbExp=5; IntAct=EBI-995373,
            EBI-355744; Q7Z434; Q9Y4K3: TRAF6; NbExp=4; IntAct=EBI-995373,
            EBI-359276; Q7Z434; Q14139: UBE4A; NbExp=2; IntAct=EBI-995373,
            EBI-1048119; Q7Z434; Q7TFA1: 7b; Xeno; NbExp=2; IntAct=EBI-995373,
            EBI-25492846; Q7Z434; P59636: 9b; Xeno; NbExp=5; IntAct=EBI-995373,
            EBI-9021274; Q7Z434; Q6WB96: M2; Xeno; NbExp=4; IntAct=EBI-995373,
            EBI-6863628; Q7Z434; Q69027: X; Xeno; NbExp=2; IntAct=EBI-995373,
            EBI-3650820; Q7Z434; A2T3M4; Xeno; NbExp=4; IntAct=EBI-995373,
            EBI-9522123; Q7Z434; P0DTD8; Xeno; NbExp=2; IntAct=EBI-995373,
            EBI-25475914; Q7Z434-1; Q9H1Y0: ATG5; NbExp=4; IntAct=EBI-15577799,
            EBI-1047414; Q7Z434-1; O95786-1: DDX58; NbExp=8;
            IntAct=EBI-15577799, EBI-15577823; Q7Z434-1; Q9BYX4: IFIH1;
            NbExp=3; IntAct=EBI-15577799, EBI-6115771; Q7Z434-1; Q86UT6-1:
            NLRX1; NbExp=3; IntAct=EBI-15577799, EBI-15680006; Q7Z434-1;
            Q96EQ8: RNF125; NbExp=2; IntAct=EBI-15577799, EBI-2339208;
            Q7Z434-1; Q86WV6: STING1; NbExp=7; IntAct=EBI-15577799,
            EBI-2800345; Q7Z434-1; P61964: WDR5; NbExp=3; IntAct=EBI-15577799,
            EBI-540834; Q7Z434-1; Q91WS2-1: Nlrp6; Xeno; NbExp=2;
            IntAct=EBI-15577799, EBI-16182226.
            [SUBCELLULAR LOCATION] Mitochondrion outer membrane
            {ECO:0000269|PubMed:16125763}. Mitochondrion
            {ECO:0000269|PubMed:11780052, ECO:0000269|PubMed:17709747,
            ECO:0000269|PubMed:20127681, ECO:0000269|PubMed:21170385,
            ECO:0000269|PubMed:25135833}. Peroxisome
            {ECO:0000269|PubMed:20451243}.
            [ALTERNATIVE PRODUCTS] Event=Alternative splicing; Named
            isoforms=6; Name=1; IsoId=Q7Z434-1; Sequence=Displayed; Name=2;
            IsoId=Q7Z434-2; Sequence=VSP_010262, VSP_010263; Name=3;
            IsoId=Q7Z434-3; Sequence=VSP_010261, VSP_010264; Name=4;
            IsoId=Q7Z434-4; Sequence=VSP_045872; Name=5; Synonyms=MAVS1b, exon
            3 deletion; IsoId=Q7Z434-5; Sequence=VSP_047817, VSP_047818;
            Name=6; Synonyms=MAVS1a, exon 2 deletion; IsoId=Q7Z434-6;
            Sequence=VSP_047816, VSP_010263.
            [TISSUE SPECIFICITY] Present in T-cells, monocytes, epithelial
            cells and hepatocytes (at protein level). Ubiquitously expressed,
            with highest levels in heart, skeletal muscle, liver, placenta and
            peripheral blood leukocytes. {ECO:0000269|PubMed:16125763,
            ECO:0000269|PubMed:16127453, ECO:0000269|PubMed:16153868}.
            [DOMAIN] The pLxIS motif constitutes an IRF3-binding motif:
            following phosphorylation by TBK1, the phosphorylated pLxIS motif
            of MAVS recruits IRF3 (PubMed:25636800). IRF3 is then
            phosphorylated and activated by TBK1 to induce type-I interferons
            and other cytokines (PubMed:25636800).
            {ECO:0000269|PubMed:25636800}.
            [DOMAIN] Both CARD and transmembrane domains are essential for
            antiviral function. The CARD domain is responsible for interaction
            with DDX58/RIG-I and IFIH1/MDA5. {ECO:0000269|PubMed:16125763}.
            [DOMAIN] The transmembrane domain and residues 300-444 are
            essential for its interaction with DHX58/LGP2.
            {ECO:0000269|PubMed:17020950}.
            [PTM] Following activation, phosphorylated by TBK1 at Ser-442 in
            the pLxIS motif (PubMed:25636800, PubMed:27302953). The
            phosphorylated pLxIS motif constitutes an IRF3-binding motif,
            leading to recruitment of the transcription factor IRF3 to induce
            type-I interferons and other cytokines (PubMed:25636800).
            {ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:27302953}.
            [PTM] (Microbial infection) Cleaved and degraded by hepatitis A
            virus (HAV) protein 3ABC allowing the virus to disrupt the
            activation of host IRF3 through the MDA5 pathway.
            {ECO:0000269|PubMed:17438296}.
            [PTM] (Microbial infection) Cleaved by the protease 2A of
            coxsackievirus B3, poliovirus and enterovirus 71 allowing the virus
            to disrupt the host type I interferon production.
            {ECO:0000269|PubMed:24390337, ECO:0000269|PubMed:28253362}.
            [PTM] Ubiquitinated (PubMed:19881509, PubMed:23087404,
            PubMed:25636800). Undergoes 'Lys-48'-linked polyubiquitination
            catalyzed by ITCH; ITCH-dependent polyubiquitination is mediated by
            the interaction with PCBP2 and leads to MAVS/IPS1 proteasomal
            degradation (PubMed:19881509). Ubiquitinated by RNF125, leading to
            its degradation by the proteasome (PubMed:17460044). Undergoes
            'Lys-48'-linked ubiquitination catalyzed by SMURF1
            (PubMed:23087404). {ECO:0000269|PubMed:17460044,
            ECO:0000269|PubMed:19881509, ECO:0000269|PubMed:23087404,
            ECO:0000269|PubMed:25636800}.
            [PTM] (Microbial infection) Cleaved by Seneca Valley virus protease
            3C allowing the virus to suppress interferon type-I production.
            {ECO:0000269|PubMed:28566380}.
            [PTM] (Microbial infection) Cleaved by HCV protease NS3/4A, thereby
            preventing the establishment of an antiviral state.
            {ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:16301520}.
            [MISCELLANEOUS] [Isoform 5]: Selectively activates an IFNbeta but
            not an IL8 promoter. Interacts with RIP1 and FADD and exhibits
            anti-viral activity against VSV infection. {ECO:0000305}.
            [SEQUENCE CAUTION] Sequence=BAA86585.1; Type=Erroneous initiation;
            Note=Extended N-terminus.; Evidence={ECO:0000305};
            Sequence=BAB14684.1; Type=Frameshift; Evidence={ECO:0000305}.
FEATURES             Location/Qualifiers
     source          1..540
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     gene            1..540
                     /gene="MAVS"
                     /gene_synonym="IPS1"
                     /gene_synonym="KIAA1271"
                     /gene_synonym="VISA"
     Protein         1..540
                     /product="Mitochondrial antiviral-signaling protein"
                     /note="MAVS; CARD adapter inducing interferon beta;
                     Interferon beta promoter stimulator protein 1; Putative
                     NF-kappa-B-activating protein 031N;
                     Virus-induced-signaling adapter; Cardif; IPS-1; VISA"
                     /UniProtKB_evidence="Evidence at protein level"
     Region          1..540
                     /region_name="Mature chain"
                     /note="Mitochondrial antiviral-signaling protein.
                     /id=PRO_0000144096."
     Region          1..513
                     /region_name="Topological domain"
                     /note="Cytoplasmic. /evidence=ECO:0000305."
     Region          1..141
                     /region_name="Splicing variant"
                     /note="Missing (in isoform 4).
                     /evidence=ECO:0000303|PubMed:14702039. /id=VSP_045872."
     Region          3..93
                     /region_name="CARD_IPS1"
                     /note="Caspase activation and recruitment domain (CARD)
                     found in IPS-1; cd08811"
                     /db_xref="CDD:260073"
     Region          3..14
                     /region_name="Helical region"
                     /note="/evidence=ECO:0000244|PDB:2VGQ."
     Region          10..77
                     /region_name="Domain"
                     /note="CARD."
     Region          10..77
                     /region_name="Region of interest in the sequence"
                     /note="Required for interaction with NLRX1.
                     /evidence=ECO:0000269|PubMed:18200010."
     Region          16..19
                     /region_name="Helical region"
                     /note="/evidence=ECO:0000244|PDB:2VGQ."
     Region          24..27
                     /region_name="Helical region"
                     /note="/evidence=ECO:0000244|PDB:2VGQ."
     Site            26
                     /site_type="mutagenized"
                     /note="E->A,R: Impairs filament formation and abolishes
                     antiviral signaling activity.
                     /evidence=ECO:0000269|PubMed:24569476."
     Region          28..30
                     /region_name="Helical region"
                     /note="/evidence=ECO:0000244|PDB:2VGQ."
     Region          36..49
                     /region_name="Helical region"
                     /note="/evidence=ECO:0000244|PDB:2VGQ."
     Region          40..131
                     /region_name="Splicing variant"
                     /note="DRLRATCTLSGNRDTLWHLFNTLQRRPGWVEYFIAALRGCELVDLADEVAS
                     VYQSYQPRTSDRPPDPLEPPSLPAERPGPPTPAAAHSIPYN ->
                     GPRTVPQTHWSHRHFLLRGQGPPHLLRPTASPTTAAERRSQVTPCLSRRPRRQSPQER
                     IQSKPCRRSAPEPSQGIQMVAPWSPPLTWQPSAL (in isoform 6).
                     /evidence=ECO:0000303|PubMed:18207245. /id=VSP_047816."
     Region          42
                     /region_name="Conflict"
                     /note="L -> P (in Ref. 8; BAC77356).
                     /evidence=ECO:0000305."
     Region          51..62
                     /region_name="Helical region"
                     /note="/evidence=ECO:0000244|PDB:2VGQ."
     Site            54
                     /site_type="mutagenized"
                     /note="T->A: Impairs ability to induce IFN-beta. Loss of
                     interaction with the ATG5-ATG12 conjugate.
                     /evidence=ECO:0000269|PubMed:16125763,
                     ECO:0000269|PubMed:17709747."
     Site            56
                     /site_type="mutagenized"
                     /note="W->A,E,R: Impairs filament formation and abolishes
                     antiviral signaling activity.
                     /evidence=ECO:0000269|PubMed:24569476."
     Region          64..148
                     /region_name="Splicing variant"
                     /note="RRPGWVEYFIAALRGCELVDLADEVASVYQSYQPRTSDRPPDPLEPPSLPA
                     ERPGPPTPAAAHSIPYNSCREKEPSYPMPVQETQ ->
                     LPTWAGEETPGGQSSGRGLDFSSLTSGAVWLWQMSDFWSCFSTWTVSIWLILHWVLLR
                     LNLQVFAKCLAQSKWPLLLPSLSCPTW (in isoform 3).
                     /evidence=ECO:0000303|PubMed:14702039. /id=VSP_010261."
     Site            67..69
                     /site_type="mutagenized"
                     /note="GWV->AAA: Impairs ability to induce IFN-beta.
                     /evidence=ECO:0000269|PubMed:16125763."
     Region          68..78
                     /region_name="Helical region"
                     /note="/evidence=ECO:0000244|PDB:2VGQ."
     Region          79
                     /region_name="Variant"
                     /note="C -> F (in dbSNP:rs11905552). /id=VAR_048609."
     Region          79
                     /region_name="Variant"
                     /note="C -> S (in dbSNP:rs11908032). /id=VAR_059197."
     Region          82..92
                     /region_name="Helical region"
                     /note="/evidence=ECO:0000244|PDB:2VGQ."
     Region          93
                     /region_name="Variant"
                     /note="Q -> E (in dbSNP:rs17857295).
                     /evidence=ECO:0000269|PubMed:14702039,
                     ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:16127453,
                     ECO:0000269|PubMed:16153868. /id=VAR_048610."
     Region          95..97
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0000244|PDB:2MS8."
     Region          98..124
                     /region_name="Splicing variant"
                     /note="RTSDRPPDPLEPPSLPAERPGPPTPAA ->
                     QFRASPADAQPQSHPKESRWWPPGVLL (in isoform 5).
                     /evidence=ECO:0000303|PubMed:14702039,
                     ECO:0000303|PubMed:18207245. /id=VSP_047817."
     Region          99..131
                     /region_name="Splicing variant"
                     /note="TSDRPPDPLEPPSLPAERPGPPTPAAAHSIPYN ->
                     ERPALALLDPQPAPWPPLSFSLSLYFLPFSVILFLVTVKR (in isoform 2).
                     /evidence=ECO:0000303|PubMed:14702039. /id=VSP_010262."
     Region          103..153
                     /region_name="Compositionally biased region"
                     /note="Pro-rich."
     Region          125..540
                     /region_name="Splicing variant"
                     /note="Missing (in isoform 5).
                     /evidence=ECO:0000303|PubMed:14702039,
                     ECO:0000303|PubMed:18207245. /id=VSP_047818."
     Region          132..540
                     /region_name="Splicing variant"
                     /note="Missing (in isoform 2 and isoform 6).
                     /evidence=ECO:0000303|PubMed:14702039,
                     ECO:0000303|PubMed:18207245. /id=VSP_010263."
     Region          143..147
                     /region_name="Region of interest in the sequence"
                     /note="Interaction with TRAF2.
                     /evidence=ECO:0000269|PubMed:16153868."
     Site            145
                     /site_type="mutagenized"
                     /note="Q->N: No interaction with TRAF2.
                     /evidence=ECO:0000269|PubMed:16153868."
     Site            148..149
                     /site_type="other"
                     /note="(Microbial infection) Cleavage; by viral Seneca
                     Valley virus protease 3C.
                     /evidence=ECO:0000269|PubMed:28566380."
     Site            148
                     /site_type="other"
                     /note="(Microbial infection) Cleavage by CV3B.
                     /evidence=ECO:0000269|PubMed:21436888."
     Site            148
                     /site_type="mutagenized"
                     /note="Q->A: Complete loss of cleavage by Seneca Valley
                     virus protease 3C. /evidence=ECO:0000269|PubMed:28566380."
     Region          149..540
                     /region_name="Splicing variant"
                     /note="Missing (in isoform 3).
                     /evidence=ECO:0000303|PubMed:14702039. /id=VSP_010264."
     Site            152
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000244|PubMed:18669648,
                     ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:24275569."
     Region          153..158
                     /region_name="Region of interest in the sequence"
                     /note="Interaction with TRAF6."
     Site            155
                     /site_type="mutagenized"
                     /note="E->D: No interaction with TRAF6; when associated
                     with D-457. /evidence=ECO:0000269|PubMed:16153868."
     Site            157
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000244|PubMed:18669648."
     Site            159
                     /site_type="mutagenized"
                     /note="Q->A: No effect on cleavage by Seneca Valley virus
                     protease 3C. /evidence=ECO:0000269|PubMed:28566380."
     Site            162
                     /site_type="mutagenized"
                     /note="Q->A: No effect on cleavage by Seneca Valley virus
                     protease 3C. /evidence=ECO:0000269|PubMed:28566380."
     Site            165
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000244|PubMed:18669648,
                     ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:24275569."
     Site            180
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000244|PubMed:24275569."
     Site            188
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000244|PubMed:24275569."
     Region          191
                     /region_name="Conflict"
                     /note="T -> N (in Ref. 9; BAF84474).
                     /evidence=ECO:0000305."
     Site            196
                     /site_type="mutagenized"
                     /note="Q->A: No effect on cleavage by Seneca Valley virus
                     protease 3C. /evidence=ECO:0000269|PubMed:28566380."
     Region          198
                     /region_name="Variant"
                     /note="Q -> K (in dbSNP:rs7262903).
                     /evidence=ECO:0000269|PubMed:15489334,
                     ECO:0000269|PubMed:16125763, ECO:0000269|PubMed:16177806.
                     /id=VAR_048611."
     Site            198
                     /site_type="mutagenized"
                     /note="Q->A: No effect on cleavage by Seneca Valley virus
                     protease 3C. /evidence=ECO:0000269|PubMed:28566380."
     Site            208..209
                     /site_type="other"
                     /note="(Microbial infection) Cleavage by protease 2A of
                     enterovirus 71. /evidence=ECO:0000269|PubMed:28253362."
     Site            209
                     /site_type="mutagenized"
                     /note="G->A: Complete loss of cleavage by protease 2A of
                     enterovirus 71. /evidence=ECO:0000269|PubMed:28253362."
     Site            215
                     /site_type="phosphorylation"
                     /note="Phosphothreonine.
                     /evidence=ECO:0000244|PubMed:24275569."
     Site            222
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000244|PubMed:16964243,
                     ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:23186163,
                     ECO:0000244|PubMed:24275569."
     Site            233
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000244|PubMed:18669648."
     Site            234
                     /site_type="phosphorylation"
                     /note="Phosphothreonine.
                     /evidence=ECO:0000244|PubMed:18669648."
     Site            236
                     /site_type="methylation"
                     /note="Asymmetric dimethylarginine.
                     /evidence=ECO:0000250|UniProtKB:Q8VCF0."
     Site            250..251
                     /site_type="other"
                     /note="(Microbial infection) Cleavage by protease 2A of
                     enterovirus 71. /evidence=ECO:0000269|PubMed:28253362."
     Site            251
                     /site_type="mutagenized"
                     /note="G->A: Complete loss of cleavage by protease 2A of
                     enterovirus 71. /evidence=ECO:0000269|PubMed:28253362."
     Site            253
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000244|PubMed:20068231."
     Site            258
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000244|PubMed:18669648,
                     ECO:0000244|PubMed:20068231."
     Site            264..265
                     /site_type="other"
                     /note="(Microbial infection) Cleavage by protease 2A of
                     enterovirus 71. /evidence=ECO:0000269|PubMed:28253362."
     Site            265
                     /site_type="mutagenized"
                     /note="G->A: Complete loss of cleavage by enterovirus 71.
                     /evidence=ECO:0000269|PubMed:28253362."
     Region          356
                     /region_name="Conflict"
                     /note="A -> V (in Ref. 8; BAC77356).
                     /evidence=ECO:0000305."
     Region          373
                     /region_name="Conflict"
                     /note="S -> P (in Ref. 8; BAC77356).
                     /evidence=ECO:0000305."
     Site            408
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000250|UniProtKB:Q8VCF0."
     Region          409
                     /region_name="Variant"
                     /note="S -> F (in dbSNP:rs7269320).
                     /evidence=ECO:0000269|PubMed:15489334,
                     ECO:0000269|PubMed:16125763, ECO:0000269|PubMed:16177806.
                     /id=VAR_018448."
     Site            427..428
                     /site_type="other"
                     /note="(Microbial infection) Cleavage; by HAV protein
                     3ABC. /evidence=ECO:0000269|PubMed:17438296."
     Site            427
                     /site_type="mutagenized"
                     /note="Q->A: No cleavage by HHAV 3ABC.
                     /evidence=ECO:0000269|PubMed:17438296."
     Site            435
                     /site_type="mutagenized"
                     /note="C->R: No effect on cleavage by NS3/4A protease
                     complex. /evidence=ECO:0000269|PubMed:16301520."
     Region          439..442
                     /region_name="Short sequence motif of biological interest"
                     /note="pLxIS motif.
                     /evidence=ECO:0000269|PubMed:25636800."
     Site            442
                     /site_type="phosphorylation"
                     /note="Phosphoserine; by TBK1.
                     /evidence=ECO:0000269|PubMed:25636800,
                     ECO:0000269|PubMed:27302953."
     Site            442
                     /site_type="mutagenized"
                     /note="S->A: Abolished ability to bind and activate IRF3.
                     /evidence=ECO:0000269|PubMed:25636800,
                     ECO:0000269|PubMed:27302953."
     Site            452
                     /site_type="mutagenized"
                     /note="C->R: No effect on cleavage by NS3/4A protease
                     complex. /evidence=ECO:0000269|PubMed:16301520."
     Region          455..460
                     /region_name="Region of interest in the sequence"
                     /note="Interaction with TRAF6."
     Region          456..459
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0000244|PDB:4Z8M."
     Site            457
                     /site_type="mutagenized"
                     /note="E->D: No interaction with TRAF6; when associated
                     with D-155. /evidence=ECO:0000269|PubMed:16153868."
     Site            463
                     /site_type="mutagenized"
                     /note="E->A: No effect on cleavage by HHAV 3ABC.
                     /evidence=ECO:0000269|PubMed:17438296."
     Region          504..507
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0000244|PDB:3RC5."
     Site            508..509
                     /site_type="other"
                     /note="(Microbial infection) Cleavage; by HCV and
                     hepatitis GB virus B NS3/4A protease complex.
                     /evidence=ECO:0000269|PubMed:16177806,
                     ECO:0000269|PubMed:16301520."
     Site            508
                     /site_type="mutagenized"
                     /note="C->A,R: No cleavage by HCV and hepatitis GB virus B
                     NS3/4A protease complex.
                     /evidence=ECO:0000269|PubMed:16177806,
                     ECO:0000269|PubMed:16301520, ECO:0000269|PubMed:17093192."
     Region          514..534
                     /region_name="Transmembrane region"
                     /note="Helical. /evidence=ECO:0000255."
     Region          535..540
                     /region_name="Topological domain"
                     /note="Mitochondrial intermembrane.
                     /evidence=ECO:0000305."
ORIGIN      
        1 mpfaedktyk yicrnfsnfc nvdvveilpy lpcltardqd rlratctlsg nrdtlwhlfn
       61 tlqrrpgwve yfiaalrgce lvdladevas vyqsyqprts drppdplepp slpaerpgpp
      121 tpaaahsipy nscrekepsy pmpvqetqap espgenseqa lqtlspraip rnpdggples
      181 ssdlaalspl tssghqeqdt elgsthtaga tssltpsrgp vspsvsfqpl arstprasrl
      241 pgptgsvvst gtsfsssspg lasagaaegk qgaesdqaep iicssgaeap anslpskvpt
      301 tlmpvntval kvpanpasvs tvpsklptss kppgavpsna ltnpapsklp instragmvp
      361 skvptsmvlt kvsastvptd gssrneetpa aptpagatgg ssawldssse nrglgselsk
      421 pgvlasqvds pfsgcfedla isastslgmg pchgpeeney ksegtfgihv aenpsiqlle
      481 gnpgppadpd ggprpqadrk fqerevpchr pspgalwlqv avtgvlvvtl lvvlyrrrlh
//

